

ALLOWANCE OF UNITED STATES PATENT

- US Patent Office issues Notice of Allowance to grant additional new patent
- Patent relates to use of Bio-Gene molecules to control resistant pests
- Along with other recent grants, this extends patent protection for Bio-Gene's technology to 2038 and further supports its core value proposition

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the 'Company'), an agtech development company enabling the next generation of novel insecticides, today announced the allowance of US patent application No. 16/629260 by the United States Patent Office (USPTO).

In July 2018, Bio-Gene submitted an international patent application designating most countries around the world, including the US, designed to extend the protection of its technology for use as pesticides, including as insecticides. The patent application focused on Flavocide™ for control of pesticide-resistant pests. The USPTO has now issued a Notice of Allowance to grant a patent containing the claims of US patent application No. 16/629260 covering the use of flavesone and related molecules to control pesticide-resistant pests. The patent will expire in July 2038. This extends current coverage for the use of flavesone and related molecules to control pesticide-resistant insect pests in an agricultural environment, and to protect stored plant parts from infestation by pesticide-resistant pests, covered by a previously granted patent. Examination of additional patent applications relating to control of resistant pests is continuing to be undertaken by other patent offices in many countries around the world.

Commenting on the successful allowance, Bio-Gene CEO, Richard Jagger said: "We are extremely pleased with the allowance of this patent application. With the USA being such a large market for our technologies patent protection creates significant value for us and our commercial partners and considerably strengthens our negotiation position for future commercial deals. We are continuing to develop commercial applications for our products supported by a number of existing and pending patents relevant to target markets throughout the world."

Approved for release by the Chairman of the Board of Directors.

- ENDS -

For further information, please contact:

<u>IR/Media</u>

Bio-Gene Technology Limited:

Richard Jagger Roger McPherson Adrian Mulcahy
Chief Executive Officer CFO & Company Secretary Automic Group
P: 03 9068 1062 P: 0438 630 422

E: bgt.info@bio-gene.com.au E: bgt.info@bio-gene.com.au E: adrian.mulcahy@automicgroup.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide



manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

Flavocide[™] and Qcide[™] are trademarks of Bio-Gene Technology Limited.